

In the Specification:

[0003] Active substances from the following groups are currently being utilised in the drug therapy of Parkinson's disease: anti-Parkinson agents having dopaminergic effect, especially L-dopa and dopamine receptor ~~antagonists~~ agonists; centrally active anti-cholinergic agents (muscarine receptor antagonists); monoamine oxidase inhibitors; NMDA antagonists; beta-sympatholytics.

[0007] An important role in the accompanying therapy of Parkinson's disease is played by the treatment with anticholinergically active substances (muscarine receptor antagonists), which particularly enables the suppression of the tremor. Substances of this group which are of therapeutical importance are, for example, ~~biperidene~~ biperiden, trihexyphenidyl, procyclidine, bormaprime, metixene, orphenadrine, scopolamine, atropine and other belladonna alkaloids, ~~benzatropine~~ benztropine and nicotine.

[00022] An important role in the accompanying therapy of Parkinson's disease is played by the treatment with anticholinergically active substances (muscarine receptor antagonists), which particularly enables the suppression of the tremor. Substances of this group which are of therapeutical importance are, for example, ~~biperidene~~ biperiden, trihexyphenidyl, procyclidine, bormaprime, metixene, orphenadrine, scopolamine, atropine and other belladonna alkaloids, ~~benzatropine~~ benztropine and nicotine.